Strategic collaborations with institutions like Massachusetts General Hospital and MD Anderson Cancer Center validate scientific rigor. The company is positioned in a market projected to reach $199.51 billion by 2034, with multiple first-in-class RNA therapeutics in development.
Cyborg Score Rationale
TransCode demonstrates solid scientific validation with early-stage clinical success and institutional partnerships, supporting its platform technology. However, the company faces typical clinical-stage risks with limited cash runway and minimal near-term revenue prospects. Recent financing (April 2026) extends runway into late 2027/early 2028, but long-term viability depends on Phase 2a trial success.
Top Insights
Phase 2a clinical trial with lead candidate TTX-MC138 is expected to begin in Q2 2026.
Phase 0 trial produced evidence of delivery to metastatic lesions; Phase 1a met safety endpoints and was well tolerated.
Company secured up to $20 million flexible financing in April 2026, comprising $6 million pre-paid advances and a three-year SEPA for up to $14 million in common stock.
Lead therapeutic candidate TTX-MC138 is designed to inhibit microRNA-10b, a genetic driver of metastatic progression linked to poor outcomes in over 200 clinical studies.